Blog
RSS FeedPosted by Michael Wonder on 20 Sep 2023
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency
20 September 2023 - NICE has published evidence-based recommendations on the use of pembrolizumab (Keytruda) for the adults with previously ...
Posted by Michael Wonder on 13 Sep 2023
Treatment options for people with glioma, a type of brain cancer
13 September 2023 - BMS, the supplier of lomustine, a treatment used for a type of brain cancer called glioma, is ...
Posted by Michael Wonder on 08 Sep 2023
Review of cancer related surrogate outcomes used for PBAC decision-making
8 September 2023 - Surrogate outcome measures have an increasingly important role in cancer medicine research providing evidence to support ...
Posted by Michael Wonder on 05 Sep 2023
Oncologists pen open letter to PHARMAC asking for more life-saving cancer drugs
5 September 2023 - Drug buying agency PHARMAC is not moving fast enough, says a gut cancer patient paying more ...
Posted by Michael Wonder on 28 Aug 2023
Efficient Funding of Chemotherapy Review – final report
28 August 2023 - The final report of the Efficient Funding of Chemotherapy Review is now available. ...
Posted by Michael Wonder on 27 Aug 2023
PHARMAC announcement of more blood cancer medicines welcomed
27 August 2023 - Myeloma New Zealand is welcoming Pharmac's announcement of more blood cancer medicines, but says the country is ...
Posted by Michael Wonder on 24 Aug 2023
PHARMAC seeking bids from suppliers for multiple myeloma treatments
24 August 2023 - PHARMAC is seeking bids from suppliers for two medicines, lenalidomide and pomalidomide, for use in the ...
Posted by Michael Wonder on 22 Aug 2023
Suggestions Nat's cancer drug funding promise has put PHARMAC in a difficult position
22 August 2023 - It's being suggested National's cancer drug funding promise has put PHARMAC in a difficult position. ...
Posted by Michael Wonder on 21 Aug 2023
National to roll back free prescription fees to pay for 13 cancer treatments
21 August 2023 - The National Party wants to bring back the $5 prescription fee for those who can afford ...
Posted by Michael Wonder on 19 Aug 2023
Quebec becomes the first province to reimburse Minjuvi (tafasitamab) in combination with lenalidomide for patients with diffuse large B-cell lymphoma
17 August 2023 - This is the first public listing since Minjuvi was approved with conditions by Health Canada in ...
Posted by Michael Wonder on 18 Aug 2023
Estimating overall survival in people receiving PBS listed cancer medicines in Australian clinical practice
18 August 2023 - In September 2021, the Department of Health and Aged Care contracted the Medicines Intelligence Centre for ...
Posted by Michael Wonder on 17 Aug 2023
Keytruda backed for 'basket' of new cancers via NHS
17 August 2023 - The UK's cost effectiveness agency NICE has recommended MSD's PD-1 inhibitor Keytruda for a series of ...
Posted by Michael Wonder on 15 Aug 2023
New treatments for people with chronic migraine and soft tissue sarcoma added to the PBS
14 August 2023 - From August 2023, Australians with chronic migraine and soft tissue sarcoma will have access to new ...
Posted by Michael Wonder on 11 Aug 2023
PHARMAC proposes widening access to a brain cancer treatment to help reduce the impact of a discontinuation
11 August 2023 - PHARMAC is proposing to widen access to temozolomide, an oral anti-cancer treatment, for people with a type ...
Posted by Michael Wonder on 03 Aug 2023
Jazz Pharmaceuticals enters into letter of intent with the pan-Canadian Pharmaceutical Alliance for Rylaze, helping address the unmet need of acute lymphoblastic leukaemia and lymphoblastic lymphoma patients across Canada
2 August 2023 - Jazz Pharmaceuticals today announced that the Company has entered into a letter of intent with the pan-Canadian ...